Episodes

  • Prise en charge des patients atteints de LLC doublement exposée et réfractaire.

    Prise en charge des patients atteints de LLC doublement exposée et réfractaire.
    Nov 18 2025

    Hosted on Acast. See acast.com/privacy for more information.
    Show More Show Less
    17 mins
  • Addressing the management of patients with double exposed and refractory CLL

    Addressing the management of patients with double exposed and refractory CLL
    Nov 18 2025
    Sponsored by Eli Lilly

    Hosted on Acast. See acast.com/privacy for more information.
    Show More Show Less
    18 mins
  • CAR T-cell Therapy in 2025: Evidence, Safety, and Patient Selection

    CAR T-cell Therapy in 2025: Evidence, Safety, and Patient Selection
    Sep 24 2025
    Sponsored by Bristol Myers Squibb.

    Hosted on Acast. See acast.com/privacy for more information.
    Show More Show Less
    25 mins
  • Practical considerations in the management of early rrMM in the Canadian context

    Practical considerations in the management of early rrMM in the Canadian context
    Jan 6 2025

    This podcast features Dr. Christopher Venner and his colleagues from the hematology community, Dr. Sylvia McCulloch, Dr. Arleigh McCurdy, and Dr. Chai Phua discussing the approach to the management of early rrMM in the Canadian context.


    This episode of Science for the Real World is part of Canadian Hematology Today, an open-access scientific journal for the hematology community.

    Hosted on Acast. See acast.com/privacy for more information.
    Show More Show Less
    32 mins
  • The role of selinexor in early rrMM and sequencing in 2024.

    The role of selinexor in early rrMM and sequencing in 2024.
    Jun 26 2024

    In this episode of "Science for the Real World: Canadian Hematology Today," Dr. Peter Anglin hosts a discussion with Dr. Joshua Richter and Dr. Darrell White on the management of early rrMM in 2024, focusing on the role of selinexor and treatment sequencing.


    Hosted on Acast. See acast.com/privacy for more information.
    Show More Show Less
    28 mins